ORTX News and Press, Orchard Therapeutics plc From 05/11/21

100% overall survival and ≥ 95% event-free survival observed at two and three years following one-time treatment with lentiviral HSC gene therapy 50 total participants represent largest published dataset of gene therapy-treated patients with a monogenic condit...

Seven abstracts accepted show the potential of HSC gene therapy to transform the treatment of multiple severe rare disorders First peer-reviewed presentation from company’s work in transduction enhancers showcases promise to improve manufacturing efficiency of lentiviral-...

An update on the 20 life sciences companies Numenor Capital has profiled so far range from cell therapy companies like SQZ Biotech and Orchard Therapeutics to biologics platforms like Pandion. The best performing investment, over 170% return, so far has been Pandion Therapeutics that ...

Wah Fu Education Group (WAFU) +82%.180 Life Sciences (ATNF) +49%.NextDecade Corporation (NEXT) +31% on signing term sheet with Occidental Petroleum.Four Seasons Education (Cayman) (FEDU) +26%.Banco Santander Mexico SA ADR (BSMX) +19%.China Liberal Education Holdings Limited (CLEU) +18%.L...

Orchard Therapeutics is the category leader for engineering and developing hematopoietic stem cell medicines. The company's platform has been validated with 2 approvals in Europe and a diverse pipeline of drug candidates. Hematopoietic stem cells have curative potential for many d...

Genetics is the study of genes, their variations and hereditary characteristics. As Live Science describes it , genetics involves looking at how traits are passed on through generations. So, what is genetics investing? When it comes to genetics investing, companies in this niche...

I have covered ORTX multiple times in the last year, and the stock saw some steady gains. However, it does not have major catalysts in the next 6 months, excluding the EU launch which may not have immediate impact. The company has adequate cash until then. For further detail...

Today Bluebird bio ([[BLUE]] +7.5%) announced that the BB305 lentiviral vector was unlikely to be the reason for the case of acute myeloid leukemia which had forced the company to halt two clinical trials for sickle cell disease (“SCD”).Noting that the update has essen...

Anchiano Therapeutics (ANCN) +66%.Second Sight Medical Products (EYES) +38%.OpGen (OPGN) +29% after publication of final study results of Unyvero HPN Panel.Net Element (NETE) +19% on strategic partnership with Mullen technologies.Athene Holding Ltd. (ATH) +18%&#x...

Orchard Therapeutics ([[ORTX]] +3.4%) has expanded its multi-year partnership with Be The Match BioTherapies, ahead of its European commercial launch of Libmeldy (autologous CD34+ cells encoding the ARSA gene).With the amended agreement, Be The Match BioTherapies which previously helped in ce...